EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
About
In this two-arm, randomized, open-label trial, asymptomatic participants with a pancreatic cyst at least 1cm in diameter will be randomly assigned in a 1:1 ratio to undergo surveillance for 5 years using a low-intensity or high-intensity strategy. The analysis will address the composite primary endpoint and several secondary and exploratory endpoints.
Eligibility Criteria
Inclusion Criteria
- Patient must be ≥ 50 years and ≤ 75 years of age.
- CT, MRI and/or EUS revealing one or more ≥ 1 cm pancreatic cyst(s)
Exclusion Criteria
- History of acute or chronic pancreatitis
- History of pancreatic resection or pancreatic malignancy
- Family history of pancreatic adenocarcinoma in first-degree relatives (parents, siblings or children)
Primary Investigator
Dr. David Salzberg is a board-certified general and bariatric surgeon. He received his M.D. from the Medical College of Virginia in Richmond, VA. Dr. Salzberg completed both his general surgery residency and transplantation fellowship at MCV. He also completed a second fellowship in bariatric surgery and advanced minimally invasive surgery at the University of California, San Francisco, CA. Dr. Salzberg joined the Department of General Surgery in 2016 and specializes in bariatric, hepatobiliary, transplant, and esophageal surgeries. He is also an assistant professor at the Virginia Tech School of Medicine. Additionally, he serves as the director of both the Carilion Clinic Metabolic Center and the Carilion Clinic/Virginia Tech Biodesign Program.
Contact Information
Bailey Steele, MPH
Clinical Research Coordinator
